|View printer-friendly version|
|April 28, 2004 5:04 p.m.|
|Teva And Alpharma Enter Into Agreement Relating To Gabapentin|
Jerusalem, Israel, April 28, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into an agreement with Alpharma Inc. (NYSE:ALO) pertaining to pending Abbreviated New Drug Applications (ANDAs) for gabapentin 600 mg and 800 mg tablets, and gabapentin 100 mg, 300 mg and 400 mg capsules, the bioequivalent versions of Pfizer's Neurontin® Tablets and Neurontin® Capsules. Neurontin® Tablets and Neurontin® Capsules had U.S. sales of over $2 billion for the twelve-month period ended December 31, 2003 according to IMS.